Navigation Links
A protein that protects against Alzheimer's?
Date:1/6/2009

ective and reparative role of this protein.

When can we expect medication?

A number of steps remain before this research can translate into effective drugs against neurodegenerative conditions. The original investigator, Professor ric Rassart, explains, "You cannot simply inject ApoD, as it has to enter the brain in order for it to be active. We have successfully demonstrated the role of ApoD, but now we need to understand the action of this protein. Only then will we be able to think about creating a drug to prevent these types of diseases and to slow their progression. All the same, this discovery by Sonia Do Carmo and her collaborators is a significant breakthrough, as we know very little about the mechanisms of neurodegenerative diseases."

The discovery has aroused considerable interest among the molecular biology community. Two major scientific journals have already published the research findings: Aging Cell (Vol. 7: 506-515, 2008) and Journal of Neuroscience (Vol. 28: 10330-10338, 2008).


'/>"/>

Contact: Claire Bouchard
bouchard.claire@uqam.ca
514-987-3000
Universit du Qubec Montral
Source:Eurekalert

Page: 1 2

Related biology news :

1. Protein chatter linked to cancer activation
2. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
3. Researchers identify proteins involved in new neurodegenerative syndrome
4. Low levels of key protein may indicate pancreatic cancer risk
5. Structure of 450 million year old protein reveals evolutions steps
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Specific brain protein required for nerve cell connections to form and function
8. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
9. Interacting protein theory awaits test from new neutron analysis tools
10. Depression, aging, and proteins made by a virus may all play role in heart disease
11. Census of protein architectures offers new view of history of life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... by wood-eating gribble that destroyed their ships, and these ... docks in coastal communities. , But new research ... the Universities of York and Portsmouth is uncovering how ... , By examining genes that are expressed in the ...
... ITHACA, N.Y. - Another weapon in the arsenal ... cancer cells while leaving healthy cells alone. Led ... Food Science, the researchers synthesized nanoparticles shaped something ... two pieces of iron oxide. They then attached antibodies, ...
... BINGHAMTON, NY -- In his recent book, "Strategic Bargaining ... Yang suggests ways governments might realistically work together to ... for curbing the use of fossil fuels whether ... global warming is factually true and I,m not ...
Cached Biology News:Seafarers' scourge provides hope for biofuel future 2Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2Cool model for a hot planet 2Cool model for a hot planet 3
(Date:7/1/2015)... ... ... Apex Therapeutics announced today that company CEO, David Broecker provided a company update ... took place on Tuesday, June 16 and provided an update on the achievement of ... of pancreatic cancer. A copy of the company overview can be found on ...
(Date:6/30/2015)... ... 2015 , ... Students and faculty from Beijing City University ... “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. ... from both universities and is taught on both continents. , “Our alliance with ...
(Date:6/30/2015)... June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... developing therapeutics that address unmet medical needs in ... Elston will present at the Cantor Fitzgerald ... 8, 2015Time: , 4:45 PM EDTLocation: , Le ... archive): , www.juniperpharma.com, under  ,Investor, or  ...
(Date:6/30/2015)... Falls Church, VA (PRWEB) , ... June 30, ... ... technology, and strategy services to the federal government, announced in a paper published ... Noblis scientists uncovered a potential problem with the diagnostic techniques currently used to ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... CRANBURY, N.J., Sept. 24 Palatin Technologies, Inc. (NYSE ... of its workforce and operations to reflect a strategic ... objectives. As a result, Palatin will focus resources and ... female sexual dysfunction and PL-3994 for acute severe asthma. ...
... 24, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Cylene Pharmaceuticals, Inc. announced today the initiation ... first-in-class, oral CK2 inhibitor CX-4945 in patients with ... of a $12 million financing with participation from ... Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, ...
Cached Biology Technology:Palatin Announces Strategic Realignment of Operations 2Palatin Announces Strategic Realignment of Operations 3Palatin Announces Strategic Realignment of Operations 4Palatin Announces Strategic Realignment of Operations 5Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 2Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 3Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 4Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 5Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 6Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 7Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 2Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 3